Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details Textual)

v3.8.0.1
License Agreements (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
May 11, 2015
May 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Mar. 31, 2015
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Neupharma [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Reimbursement Of Cost Recognized As Revenue           $ 31,000 $ 200,000    
Payment Of Upfront Licensing Fee         $ 1,000,000        
Payment For Non refundable Milestone payments               $ 1,000,000  
Neupharma [Member] | Additional Sales Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments           22,500,000      
Neupharma [Member] | Clinical Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments           40,000,000      
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments           40,000,000      
Dana-Farber [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Shares Issued, Price Per Share $ 0.065                
Stock Issued During Period, Shares, Issued for Services 500,000     136,830          
Stock Issued During Period, Value, Issued for Services $ 32,500     $ 600,000          
Payment of Upfront Fees         1,000,000        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 5.00%                
Proceeds from Issuance of Common Stock $ 10,000,000                
Dana-Farber [Member] | First Commercial Sale Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due           21,500,000      
Maximum Potential Milestone Payments           21,500,000      
Dana-Farber [Member] | Additional Sales Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due           60,000,000      
Maximum Potential Milestone Payments           60,000,000      
Teva Pharmaceutical Industries Ltd [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Payment of Upfront Fees     $ 500,000            
Teva Pharmaceutical Industries Ltd [Member] | Clinical Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments           220,000,000      
Teva Pharmaceutical Industries Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments           206,500,000      
Jubilant Biosys Ltd [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Payment of Upfront Fees   $ 2,000,000              
Revenue Recognition, Milestone Method, Revenue Recognized           $ 268,000 464,000    
Research and Development Cost, Shared Percentage           50.00%      
Non-Refundable Milestone Payment                 $ 400,000
Jubilant Biosys Ltd [Member] | Clinical Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due           $ 89,000,000      
Maximum Potential Milestone Payments           89,000,000      
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments           59,500,000      
Jubilant Biosys Ltd [Member] | Successful Achievement Of One Preclinical Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due           25,500,000      
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments           61,700,000      
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments           89,000,000      
Jubilant Sublicense [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due           87,200,000      
Proceeds from Upfront Fees   $ 1,000,000              
Collaboration Agreement With TGTX [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition, Milestone Method, Revenue Recognized           44,000 $ 28,000    
Proceeds From Upfront Licensing Fee         $ 500,000        
Collaboration Agreement With TGTX [Member] | Clinical Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due           7,000,000      
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due           $ 14,500,000